Pipeline
UI-102
UI-102 is a PNP-encapsulated TLR7/8 agonist currently in a Phase 1/2 clinical trial for the treatment of solid tumors. UI-102 is designed to reprogram immunosuppressive, pro-tumor M2-like tumor-associated macrophages (TAMs) into inflammatory, anti-tumor M1-like TAMs, thereby converting “cold” tumors into “hot,” immunotherapy-responsive ones. By enabling localized immune activation, UI-102 has the potential to improve outcomes in patients who do not respond to current immunotherapies while reducing the risk of systemic toxicities, including cytokine release syndrome (CRS) a known concern with TLR7 and/or TLR8 agonists.